Myelin Foundry | $4,000,000 | (May 9, 2024)
Rad AI | $50,000,000 | (May 9, 2024)
Definely | $7,000,000 | (May 9, 2024)
Aryastha Life Sciences
India
- Hyderabad, Telangana
- 29/08/2023
- Series A
- Undisclosed Amount
Aryastha Life Science shines as a beacon of innovation and leadership, illuminating the pharmaceutical and biotechnology sectors. We fearlessly address and deliver the intricate challenges within drug discovery and development with unwavering determination. Our foundation is built upon years of transformative experience, culminating in Aryastha's inception. Aryastha represents the culmination of dedicated efforts to overcome scientific barriers spanning various facets of drug discovery and development. Our overarching mission is to provide innovative and integrated solutions that de-risk and streamline drug discovery and development, driving toward a healthier future. We are committed to add value by understanding the unique needs of our clients, collaborating with global Biotech and Pharmaceutical partners, and leveraging our capabilities to fuel advancements in healthcare.
- Industry Research Services
- Website https://www.aryastha.com/
- LinkedIn https://www.linkedin.com/company/aryastha-life-sciences/about/
Related People
Raghava Reddy KethiriCo Founder
India -
Greater Hyderabad Area
Raghava is a German national of Indian origin with over 28 years of experience as an Entrepreneur & Scientific innovator working in Pharmaceutical industry & Academia.
His career started as Alexander von Humboldt (AvH) fellow at Karlsruhe University of Applied Sciences, Germany after completing PhD in Organic Chemistry from India. Since then he has held various senior positions in academia & pharmaceutical industry in Germany and India and worked on several drug discovery projects including integrated with various large-/mid-sized pharma’s along with small biotech and virtual companies and has taken compounds from target to clinic and delivered several optimized leads across diverse therapeutic areas viz., Oncology, Pain & CNS, MD and Antibacterial. Co-inventor two Clinical Candidates ASN-001 (NCT 02349139) for Metastatic Castration Resistant Prostate Cancer for Phase1/2 clinical trials and ASN-007 (NCT 03415126) for metastatic KRAS, NRAS and HRAS mutated solid tumors out licensed to Erasca ERAS-007 (NCT 05039177) for currently in Phase1b/2, studies for an Advanced Gastrointestinal Malignancies. Further two projects are currently at the PCC nomination IND enabling studies.
Raghava is a Co-inventor / co-author of more than 60 research publications, patents, invited review articles, perspectives and book chapters. He is a member of several active chemical societies and reviewer of peer reviewed journals and committees. Strong intercultural leadership skills managing Investments and international multidisciplinary project teams across various geographical regions .
Since May 2023, he is the Co-Founder & CEO of ARYASTHA Life Sciences. Prior to this he was associated with LAXAI Life Sciences as Chief Scientific Officer and Board of Directors, Jubilant Biosys., Bangalore, India, Technical University of Dresden (TUD), Germany, Karlsruhe Institute of Technology (KIT), Germany, IIT Kanpur and NEHU, Shillong, India.
RunPod | $20,000,000 | (May 9, 2024)
Greenboard | $4,500,000 | (May 9, 2024)
Provable Markets | $8,000,000 | (May 9, 2024)
Lucid Bots | $9,100,000 | (May 9, 2024)
RLP, Rapid Liquid Print | $7,000,000 | (May 9, 2024)
In-House Health | $4,000,000 | (May 9, 2024)
Arbelos Markets | $28,000,000 | (May 9, 2024)
Ciba Health | $10,000,000 | (May 9, 2024)
Panax | $10,000,000 | (May 9, 2024)